HUP9801777A3 - Use of vitamin d2 or vitamin d4-derivatives for the manufacture of a medicament for the treatment of secondary hyperparathyroidism - Google Patents

Use of vitamin d2 or vitamin d4-derivatives for the manufacture of a medicament for the treatment of secondary hyperparathyroidism

Info

Publication number
HUP9801777A3
HUP9801777A3 HU9801777A HUP9801777A HUP9801777A3 HU P9801777 A3 HUP9801777 A3 HU P9801777A3 HU 9801777 A HU9801777 A HU 9801777A HU P9801777 A HUP9801777 A HU P9801777A HU P9801777 A3 HUP9801777 A3 HU P9801777A3
Authority
HU
Hungary
Prior art keywords
vitamin
medicament
derivatives
manufacture
treatment
Prior art date
Application number
HU9801777A
Other languages
English (en)
Original Assignee
Bone Care International Inc Ma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23645881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP9801777(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bone Care International Inc Ma filed Critical Bone Care International Inc Ma
Publication of HUP9801777A2 publication Critical patent/HUP9801777A2/hu
Publication of HUP9801777A3 publication Critical patent/HUP9801777A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/22—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
HU9801777A 1995-04-03 1996-04-03 Use of vitamin d2 or vitamin d4-derivatives for the manufacture of a medicament for the treatment of secondary hyperparathyroidism HUP9801777A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/415,488 US5602116A (en) 1988-08-02 1995-04-03 Method for treating and preventing secondary hyperparathyroidism

Publications (2)

Publication Number Publication Date
HUP9801777A2 HUP9801777A2 (hu) 1998-11-30
HUP9801777A3 true HUP9801777A3 (en) 1999-05-28

Family

ID=23645881

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9801777A HUP9801777A3 (en) 1995-04-03 1996-04-03 Use of vitamin d2 or vitamin d4-derivatives for the manufacture of a medicament for the treatment of secondary hyperparathyroidism

Country Status (18)

Country Link
US (3) US5602116A (hu)
EP (1) EP0820290B1 (hu)
JP (1) JP3529790B2 (hu)
KR (1) KR100432265B1 (hu)
CN (1) CN1214795C (hu)
AU (1) AU719773B2 (hu)
BR (1) BR9604940A (hu)
CA (1) CA2217260C (hu)
DE (1) DE69629184T2 (hu)
ES (1) ES2206570T3 (hu)
FI (1) FI973868A (hu)
HK (1) HK1008180A1 (hu)
HU (1) HUP9801777A3 (hu)
MX (1) MX9707535A (hu)
NO (1) NO974480L (hu)
NZ (1) NZ316662A (hu)
PL (1) PL322613A1 (hu)
WO (1) WO1996031215A1 (hu)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602116A (en) * 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US20040009958A1 (en) * 1991-01-08 2004-01-15 Bone Care International, Inc. Methods for preparation and use of 1alpha,24(S)-dihydroxyvitamin D2
US5763429A (en) 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
US6242434B1 (en) * 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US20040043971A1 (en) * 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US20020183288A1 (en) * 1995-04-03 2002-12-05 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US20020128240A1 (en) * 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US6503893B2 (en) * 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
US6566353B2 (en) 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
US6573256B2 (en) 1996-12-30 2003-06-03 Bone Care International, Inc. Method of inhibiting angiogenesis using active vitamin D analogues
US20030129194A1 (en) * 1997-02-13 2003-07-10 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
HUP0002454A2 (hu) * 1997-02-13 2000-12-28 Bone Care International, Inc. D-Vitamin-molekularésszel rendelkező konjugátumok és ilyen konjugátumokat tartalmazó gyógyászati készítmények
US5962030A (en) 1997-03-07 1999-10-05 Akesis Pharmaceuticals, Inc. Dietary supplement and method of treatment for diabetic control
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
AU762481C (en) * 1998-03-27 2004-08-19 Oregon Health Sciences University Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders
US6376549B1 (en) * 1998-09-17 2002-04-23 Akesis Pharmaceuticals, Inc. Metforimin-containing compositions for the treatment of diabetes
US6852760B1 (en) 1998-09-17 2005-02-08 Akesis Pharmaceuticals, Inc. Compositions and methods for treatment for glucose metabolism disorders
WO2001064251A2 (en) * 2000-03-02 2001-09-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Combination chemotherapy
WO2002006218A2 (en) * 2000-07-18 2002-01-24 Bone Care International, Inc. STABILIZED 1α-HYDROXY VITAMIN D
AU1348302A (en) * 2000-10-13 2002-04-22 Abbott Lab A method of determining the initial dose of vitamin d compounds
US7129230B2 (en) 2001-03-12 2006-10-31 Nestec S.A. Method and product for treating cancer in pets
KR100438254B1 (ko) * 2001-03-29 2004-07-02 아이큐어 주식회사 비타민 ｄ 유사체를 포함하는 매트릭스형 경피흡수제제
ES2192136B1 (es) * 2002-01-04 2005-03-16 Italfarmaco, S.A. Composiciones farmaceuticas para el tratamiento o prevencion de la osteoporosis.
US7566696B2 (en) 2002-09-05 2009-07-28 Wisconsin Alumni Research Foundation Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
WO2004028515A1 (en) * 2002-09-26 2004-04-08 Young-Kweon Choi Matrix type patch for transdermal administration of vitamin d analog and the use thereof
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
US8093423B2 (en) 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
WO2004098617A2 (en) * 2003-05-07 2004-11-18 Osteologix A/S Controlled release composition containing a strontium salt
SI1622630T1 (sl) * 2003-05-07 2012-12-31 Osteologix A/S Stroncijeva kombinacije za profilakso/zdravljenje patologij hrustanca in/ali kosti
JP4354984B2 (ja) * 2003-05-07 2009-10-28 オステオロジックス エイ／エス 水溶性ストロンチウム塩を用いる軟骨／骨症状の治療
WO2005102355A1 (en) * 2004-04-23 2005-11-03 Genzyme Corporation METHODS OF TREATING VARIOUS VITAMIN D METABOLISM CONDITIONS WITH 1α-HYDROXYVITAMIN D2
US20060003950A1 (en) * 2004-06-30 2006-01-05 Bone Care International, Inc. Method of treating prostatic diseases using a combination of vitamin D analogues and other agents
US7094775B2 (en) * 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
EP1848455A1 (en) * 2005-02-14 2007-10-31 Wisconsin Alumni Research Foundation Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis
CA2924200C (en) * 2005-10-12 2017-09-05 Proventiv Therapeutics, Llc Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency
ES2580127T3 (es) * 2006-01-30 2016-08-19 Panion & Bf Biotech Inc. Procedimiento de tratamiento de la nefropatía crónica
HUE029572T2 (hu) * 2006-02-03 2017-03-28 Opko Renal Llc D-vitamin-elégtelenség és -hiány kezelése 25-hidroxi-D2-vitaminnal és 25-hidroxi-D3-vitaminnal
US8329677B2 (en) 2006-06-21 2012-12-11 Cytochroma, Inc. Method of treating and preventing secondary hyperparathyroidism
AU2007325387B2 (en) * 2006-11-16 2014-04-03 Kai Pharmaceuticals, Inc. Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders
WO2008134523A1 (en) 2007-04-25 2008-11-06 Proventiv Therapeutics, Llc Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
WO2008134518A2 (en) * 2007-04-25 2008-11-06 Cytochroma Inc. Methods and compounds for vitamin d therapy
EP3542792B1 (en) 2007-04-25 2023-06-28 EirGen Pharma Ltd. Controlled release 25-hydroxyvitamin d
KR101495578B1 (ko) * 2007-04-25 2015-02-25 사이토크로마 인코포레이티드 비타민 ｄ 부족 및 결핍의 치료 방법
KR101852042B1 (ko) 2008-04-02 2018-04-25 사이토크로마 인코포레이티드 비타민 ｄ 결핍 및 관련 장애에 유용한 방법, 조성물, 용도 및 키트
RU2563819C2 (ru) 2009-07-21 2015-09-20 Керикс Байофармасьютикалз, Инк. Лекарственные формы цитрата железа (iii)
ES2607954T3 (es) 2009-07-29 2017-04-04 Kai Pharmaceuticals, Inc. Agentes terapéuticos para reducir los niveles de hormona paratiroidea
US7886904B1 (en) * 2009-07-30 2011-02-15 Owens Corning Intellectual Capital, Llc Loosefill package for blowing wool machine
LT2552484T (lt) 2010-03-29 2020-04-27 Opko Ireland Global Holdings, Ltd. Būdai ir kompozicijos, skirti paratiroidų lygiams sumažinti
CA2698160C (en) * 2010-03-30 2017-07-25 Alphora Research Inc. Stabilized doxercalciferol and process for manufacturing the same
BR112012026361A2 (pt) * 2010-04-16 2019-09-24 Baxter Healthcare Sa previsão de terapia e otimização de terapia sanguínea para insuficiência renal, especialmente hemodiálise domiciliar
BR112013031539A2 (pt) 2011-06-08 2019-07-30 Kai Pharmaceuticals Inc agentes terapêuticos para regular fósforo sérico
EP2776129B2 (en) 2011-11-10 2020-06-17 Kai Pharmaceuticals, Inc. Compositions for use in the treatment of chronic kidney disease-mineral bone disorder characterized by soft tissue calcification
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
MX2016010892A (es) * 2014-02-26 2016-11-17 Nippon Zoki Pharmaceutical Co Agente para suprimir el progreso de o para mejorar la enfermedad renal cronica.
CN114681468A (zh) 2014-08-07 2022-07-01 欧普科爱尔兰环球控股有限公司 利用25-羟基维生素d的辅助疗法
JP6520510B2 (ja) * 2015-07-15 2019-05-29 富士ゼロックス株式会社 情報処理装置及び情報処理プログラム
TW202214257A (zh) 2016-03-28 2022-04-16 愛爾蘭商歐科愛爾蘭全球控股股份有限公司 維生素d治療之方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3907843A (en) * 1974-06-14 1975-09-23 Wisconsin Alumni Res Found 1{60 -Hydroxyergocalciferol and processes for preparing same
US4202829A (en) * 1978-01-05 1980-05-13 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4195027A (en) * 1978-01-16 1980-03-25 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4260549A (en) * 1979-05-21 1981-04-07 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4225596A (en) * 1978-10-13 1980-09-30 Wisconsin Alumni Research Foundation Method for treating calcium imbalance and improving calcium absorption in mammals
US4234495A (en) * 1979-09-10 1980-11-18 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxyvitamin D compounds from 1α-hydroxy-3,5-cyclovitamin D compounds
US4554106A (en) * 1984-11-01 1985-11-19 Wisconsin Alumni Research Foundation Method for preparing 1α-hydroxyvitamin D compounds
US4555364A (en) * 1984-11-01 1985-11-26 Wisconsin Alumni Research Foundation Method for preparing 1-hydroxyvitamin D compounds
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
US4833125A (en) * 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
US5602116A (en) * 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US5104864A (en) * 1988-08-02 1992-04-14 Bone Care International, Inc. Method for treating and preventing loss of bone mass
GB2229921B (en) * 1989-04-05 1992-12-16 Chugai Pharmaceutical Co Ltd Treatment for hyperparathyroidism with use of vitamin d derivatives
ES2169023T3 (es) * 1990-09-21 2002-07-01 Bone Care Int Inc Nueva 1alfa-hidroxi vitaminada d4 y nuevos intermedios y analogos.
ATE240736T1 (de) * 1991-01-08 2003-06-15 Bone Care Int Inc Verfahren zur herstellung von 1-alpha-24- dihydroxy-vitamin d2
DK0503630T3 (da) * 1991-03-13 1996-01-29 Kuraray Co Cyclohexantriolderivater
CA2129120A1 (en) * 1992-01-29 1993-08-05 Joyce C. Knutson 1.alpha.-hydroxy-24-epi-vitamin d4
EP0562497A1 (en) * 1992-03-27 1993-09-29 Nisshin Flour Milling Co., Ltd. 1 alpha-hydroxy vitamins D7 and D4' processes for the preparation thereof and pharmaceutical compositions
EP0614456B1 (en) * 1992-08-28 1999-06-09 Bone Care International, Inc. 1alpha,24(s)-dihydroxy vitamin d2, its formation and use
US5350745A (en) * 1993-01-29 1994-09-27 Lunar Corporation Treatment of myocardial failure

Also Published As

Publication number Publication date
WO1996031215A1 (en) 1996-10-10
FI973868A0 (fi) 1997-10-02
PL322613A1 (en) 1998-02-02
HUP9801777A2 (hu) 1998-11-30
ES2206570T3 (es) 2004-05-16
KR19980703537A (ko) 1998-11-05
AU719773B2 (en) 2000-05-18
CA2217260C (en) 2000-08-01
JP3529790B2 (ja) 2004-05-24
NZ316662A (en) 2001-04-27
US5861386A (en) 1999-01-19
KR100432265B1 (ko) 2004-09-10
NO974480D0 (no) 1997-09-29
US5707980A (en) 1998-01-13
EP0820290A1 (en) 1998-01-28
AU5384096A (en) 1996-10-23
US5602116A (en) 1997-02-11
CN1185109A (zh) 1998-06-17
MX9707535A (es) 1998-07-31
EP0820290B1 (en) 2003-07-23
CA2217260A1 (en) 1996-10-10
CN1214795C (zh) 2005-08-17
NO974480L (no) 1997-11-14
FI973868A (fi) 1997-10-02
DE69629184T2 (de) 2004-05-06
HK1008180A1 (en) 1999-05-07
DE69629184D1 (de) 2003-08-28
JPH11503164A (ja) 1999-03-23
BR9604940A (pt) 1998-06-09

Similar Documents

Publication Publication Date Title
HUP9801777A3 (en) Use of vitamin d2 or vitamin d4-derivatives for the manufacture of a medicament for the treatment of secondary hyperparathyroidism
HK1054704A1 (en) Disposable sanitary mask.
EP0764452A3 (de) Atemschutzmaske
AU3541095A (en) Surgical face mask
HK1041489A1 (en) 5-0-Desosaminyl 6-0-methylerythronolide a for use for the preparation of bilogically-active products
HUP9901089A3 (en) Medical splint
EP0740937A3 (fr) Utilisation de rétinoides pour la fabrication d'une composition cosmétique ou pharmaceutique
AU3728095A (en) Use of zaprinast for the manufacture of a medicament for inhibiting vascular restenosis
AU7310896A (en) Use of nitroflavonoids for the treatment of anxiety
AU1116895A (en) Use of theophylline for the manufacture of a medicament for the treatment of asthma
HUP9901303A3 (en) A pharmaceutical composition for the treatment of autoimmune diseases
AU2787495A (en) Use of copolymer-1 for the manufacture of a medicament for the treatment of optic neuritis
EP0765661A3 (en) Use of docosahexaenoic acid for the manufacture of a medicament for the treatment of glumerulonephritis
AU2739497A (en) Use of vitamin d analogs for the treatment of arthritic disease
HRP960045B1 (en) Combination therapy for hiv infection
AU5518694A (en) Treatment of a group of related disorders
GB2282126B (en) An aid for the transfer of patients
AU1348895A (en) Use of a tricyclic compound for obtaining medicinal products intended for the treatment of memory/cognitive disorders
AU7726796A (en) Use of 3-oxa-d-prostaglandins for the manufacture of a medicament for the treatment of glaucoma
AU4081393A (en) Medicaments for the treatment of anxiety
EP0783891A4 (en) REMEDY FOR BONE DISEASES
GB9524942D0 (en) Drug therapy
AU4297696A (en) Use of a vitamin of the k group for treating hyperparathyroidism
SI0778025T1 (en) Use of 8,9-dehydroestrone for the manufacture of a medicament for the treatment of diseases caused by free radicals
AU6097394A (en) Method for the treatment of respiratory disease